J Korean Ophthalmol Soc.  2011 Jul;52(7):771-776. 10.3341/jkos.2011.52.7.771.

Risk Factors for Dry Eye in Thyroid-Associated Ophthalmopathy

• Kim JR
• Yim HB
• Chung SK

• KMID: 2214699
• DOI: http://doi.org/10.3341/jkos.2011.52.7.771

Abstract

PURPOSE
To investigate the risk factors for dry eye in thyroid-associated ophthalmopathy patients.
METHODS
The present retrospective study was conducted on 78 eyes in 39 patients diagnosed with thyroid-associated ophthalmopathy. The risk factors for dry eye in thyroid-associated ophthalmopathy patients were examined by analyzing data including tear break-up time, Schirmer's test, age, gender, thyroid function status, palpebral fissure width, lagophthalmos, eyelid retraction, and exophthalmos through multiple logistic regression analysis.
RESULTS
The risk factors for dry eye disease were palpebral fissure width (OR = 3.422, p = 0.022) and lagophthalmos (OR = 13.068, p = 0.049). Age, gender, thyroid hormone status, eyelid retraction and exophthalmos did not show significant association with dry eye in multiple logistic regression analysis. The only risk factor for tear film break-up time less than 10 seconds was palpebral fissure width (OR = 2.787, p = 0.045), and none of the risk factors for Schirmer's test less than 10 mm at 5 minutes were statistically significant.
CONCLUSIONS
Risk factors for dry eye in thyroid ophthalmopathy patients were palpebral fissure width and lagophthalmos.

Keyword

Dry eye syndrome; Risk factors; Thyroid-associated ophthalmopathy

MeSH Terms

Dry Eye Syndromes
Exophthalmos
Eye
Eye Diseases
Eyelids
Graves Ophthalmopathy
Humans
Logistic Models
Retrospective Studies
Risk Factors
Tears
Thyroid Gland

Reference

References

1. Rootman J, Dolman PJ. Thyroid Orbitopathy. 2nd ed.Philadelphia: Lippincott Williams & Wilkins;2003. p. 169–212.

2. Char DH. Thyroid eye disease. Br J Ophthalmol. 1996; 80:922–6.

3. Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol. 1983; 61:108–16.

4. Brasil MV, Brasil OF, Vieira RP, et al. Tear film analysis and its relation with palpebral fissure height and exophthalmos in Graves' ophthalmopathy. Arq Bras Oftalmol. 2005; 68:615–8.

5. Tsai CC, Kau HC, Kao SC, Hsu WM. Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye. 2006; 20:569–73.

6. Tellez M, Cooper J, Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol. 1992; 36:291–4.

7. Woo KI, Kim YD, Lee SY; Korean Society of Ophthalmic Plastic and Reconstructive Surgery. The clinical characteristics of thyroid orbitopathy in thyroid dysfunction patients in Korea. J Korean Ophthalmol Soc. 2008; 49:1387–96.

8. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996; 121:284–90.

9. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006; 91:3464–70.

10. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol. 2000; 52:267–71.

11. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol. 1997; 47:9–14.

12. Kaercher T, Bron AJ. Classification and diagnosis of dry eye. Dev Ophthalmol. 2008; 41:36–53.

13. Lemp MA, Dohlman CH, Kuwabara T, et al. Dry eye secondary to mucus deficiency. Trans Am Acad Ophthalmol Otolaryngol. 1971; 75:1223–7.

14. Jones LT. The lacrimal secretory system and its treatment. Am J Ophthalmol. 1966; 62:47–60.

15. Moses RA. The Eyelid. 8th ed.St. Louis: Mosby;1987. p. 11–36.

16. Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of Graves' orbitopathy vary with age and sex. Arch Ophthalmol. 1993; 111:197–201.

17. Ko DA, Kim BJ, Kazim M. The epidemiologic and clinical characteristics of thyroid-associated orbitopathy. J Korean Ophthalmol Soc. 2006; 47:683–9.

18. Kohn LD, Harii N. Thyrotropin receptor autoantibodies (TSHRAbs): epitopes, origins and clinical significance. Autoimmunity. 2003; 36:331–7.

19. Kim WB, Chung HK, Park YJ, et al. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies. Korean J Intern Med. 2001; 16:187–200.

20. Kim WB, Chung HK, Park YJ, et al. The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease. Thyroid. 2000; 10:579–86.

21. Gomez JM, Soler J, Navarro MA. Thyroid stimulating antibodies in patients with Graves' ophthalmopathy. Thyroidology. 1991; 3:59–61.

22. Oh HJ, You IC, Yoon KC. Changes of tear parameters after using cyclosporine a in dry eye with thyroid ophthalmopahty. J Korean Ophthalmol Soc. 2007; 48:630–6.

23. Wiersinga WM, Prummel MF. Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab. 2002; 13:280–7.

24. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009; 3:405–12.

25. Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). Ophthalmic Epidemiol. 2009; 16:15–21.

26. Sahai A, Malik P. Dry eye: prevalence and attributable risk factors in a hospital-based population. Indian J Ophthalmol. 2005; 53:87–91.

27. Calonge M, Diebold Y, Sáez V, et al. Impression cytology of the ocular surface: a review. Exp Eye Res. 2004; 78:457–72.

28. Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008; 92:1275–82.

29. Xiong C, Chen D, Liu J, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci. 2008; 49:1850–6.